We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer

    San-Gang Wu‡

    Department of Radiation Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Fujian, 361003, PR China

    ‡Authors contributed equally

    Search for more papers by this author

    ,
    Wen-Wen Zhang‡

    Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong, 510060, PR China

    ‡Authors contributed equally

    Search for more papers by this author

    ,
    Jun Wang

    Department of Radiation Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Fujian, 361003, PR China

    Search for more papers by this author

    ,
    Chen-Lu Lian

    Department of Radiation Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Fujian, 361003, PR China

    Search for more papers by this author

    ,
    Jia-Yuan Sun

    Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong, 510060, PR China

    Search for more papers by this author

    ,
    Yong-Xiong Chen

    *Author for correspondence: Tel.: +86 592 2183761; Fax: +86 592 2186786;

    E-mail Address: yxchen1962@xmu.edu.cn

    Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology & Visual Science, Medical College, Xiamen University, Fujian, 361005, PR China

    Search for more papers by this author

    &
    Zhen-Yu He

    **Author for correspondence: Tel.: +86 20 87343543; Fax: +86 20 87343392;

    E-mail Address: hezhy@sysucc.org.cn

    Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong, 510060, PR China

    Search for more papers by this author

    Published Online:25 Jun 2019https://doi.org/10.2217/bmm-2019-0209

    Abstract

    Aim: To assess the association between established clinicopathological variables and the 21-gene recurrence score (RS) stratification of invasive lobular carcinoma (ILC) of the breast. Materials & methods: We identified 9030 ILC patients from the Surveillance, Epidemiology and End Results database. Results: Older age, higher grade tumor and progesterone receptor (PR)-negative disease were independent predictors of high-risk RS stratification. Among patients with PR-positive tumors, 3, 6 and 15% with well-differentiated (G1), moderately-differentiated (G2) and poorly and/or undifferentiated (G3) disease were in the high-risk cohort, respectively. In patients with PR-negative tumors: 16, 24 and 41% of patients with G1, G2 and G3 disease were in the high-risk cohort, respectively. Conclusion: The 21-gene RS testing may not be necessary for patients with PR+/G1–2 ILC.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817–2826 (2004).
      Medline CASGoogle Scholar
    • 2. Sparano JA, Gray RJ, Makower DF et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379(2), 111–121 (2018).
      Medline CASGoogle Scholar
    • 3. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28(11), 1829–1834 (2010).
      MedlineGoogle Scholar
    • 4. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
      MedlineGoogle Scholar
    • 5. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J. Clin. Oncol. 23(1), 41–48 (2005).
      MedlineGoogle Scholar
    • 6. McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res. 17, 12 (2015). • Evaluates the morphology and biomarkers of invasive lobular carcinoma (ILC).
      MedlineGoogle Scholar
    • 7. Loibl S, Volz C, Mau C et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res. Treat. 144(1), 153–162 (2014).
      Medline CASGoogle Scholar
    • 8. Siegelmann-Danieli N, Silverman B, Zick A, Beit-Or A, Katzir I, Porath A. The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience 7, 380 (2013).
      MedlineGoogle Scholar
    • 9. Wang J, He ZY, Dong Y, Sun JY, Zhang WW, Wu SG. The distribution and outcomes of the 21-gene recurrence score in T1-T2N0 estrogen receptor-positive breast cancer with different histologic subtypes. Front. Genet. 9, 638 (2018). •• Evaluates the distribution of 21-gene recurrence score (RS) in different histological subtypes.
      Medline CASGoogle Scholar
    • 10. Chen XH, Zhang WW, Wang J et al. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer. Biomark. Med. 13(2), 83–93 (2019).
      CASGoogle Scholar
    • 11. Davidson JA, Cromwell I, Ellard SL et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. Eur. J. Cancer 49(11), 2469–2475 (2013).
      Medline CASGoogle Scholar
    • 12. Holt S, Bertelli G, Humphreys I et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br. J. Cancer 108(11), 2250–2258 (2013).
      Medline CASGoogle Scholar
    • 13. National Cancer Institute, DCCPS. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs (Excl AK) Custom Data Malignant Breast (with Oncotype DX and Additional Treatment Fields), Nov 2017 Sub (2004–2015) - linked To county attributes - Total US, 1969–2016 counties (2018(www.seer.cancer.gov).
      Google Scholar
    • 14. NCI_SEER_Overview. Overview of the SEER program. Surveillance Epidemiology and End Results (2015). http://seer.cancer.gov/about/.
      Google Scholar
    • 15. Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An analysis of oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J. 23(6), 677–686 (2017). • Evaluates the role of 21-gene RS in ILC.
      MedlineGoogle Scholar
    • 16. Wilson PC, Chagpar AB, Cicek AF et al. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. Breast J. 24(6), 976–980 (2018).
      Medline CASGoogle Scholar
    • 17. Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res. Treat. 165(3), 757–763 (2017). •• Evaluates the role of 21-gene RS in ILC.
      MedlineGoogle Scholar
    • 18. Sun JY, Wu SG, Li FY, Lin HX, He ZY. Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. Onco Targets Ther. 9, 1707–1713 (2016).
      Medline CASGoogle Scholar
    • 19. Bae SY, Kim S, Lee JH et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 15, 138 (2015).
      MedlineGoogle Scholar
    • 20. Prat A, Cheang MC, Martín M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 31(2), 203–209 (2013).
      Medline CASGoogle Scholar
    • 21. Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16(3), 276–285 (2011).
      Medline CASGoogle Scholar
    • 22. Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol. Oncol. Stem Cell Ther. 9(2), 48–54 (2016). • Evaluates the relevance of PR status and 21-gene RS stratification.
      Medline CASGoogle Scholar
    • 23. Onoda T, Yamauchi H, Yagata H et al. The value of progesterone receptor expression in predicting the recurrence score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 22(4), 406–412 (2015).
      MedlineGoogle Scholar
    • 24. Huang JL, Kizy S, Marmor S et al. Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma. Breast Cancer Res. Treat. 172(3), 671–677 (2018). •• Evaluates the role of tumor grade and PR status in 21-gene RS stratification of breast cancer.
      Medline CASGoogle Scholar
    • 25. Amin MB, Edge SB. AJCC Cancer Staging Manual. Springer, NY, USA (2017).
      Google Scholar
    • 26. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 108(2), 191–201 (2008).
      Medline CASGoogle Scholar
    • 27. Natrajan R, Lambros MB, Geyer FC et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 48(4), 351–365 (2009).
      Medline CASGoogle Scholar
    • 28. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726–3734 (2006).
      Medline CASGoogle Scholar
    • 29. Clark BZ, Dabbs DJ, Cooper KL, Bhargava R. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Appl. Immunohistochem. Mol. Morphol. 21(4), 287–291 (2013).
      Medline CASGoogle Scholar
    • 30. Tsai ML, Lillemoe TJ, Finkelstein MJ et al. Utility of oncotype DX risk assessment in patients with invasive lobular carcinoma. Clin. Breast Cancer 16(1), 45–50 (2016). •• Evaluates the role of 21-gene RS in ILC.
      MedlineGoogle Scholar
    • 31. Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating tumor characteristics to maximize 21-gene assay utility: a cost–effectiveness analysis. J. Natl Compr. Canc. Netw. 17(1), 39–46 (2019). •• Evaluates the role of tumor characteristics in 21-gene RS stratification.
      Medline CASGoogle Scholar
    • 32. Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost–effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J. Clin. Oncol. 36(16), 1619–1627 (2018).
      MedlineGoogle Scholar
    • 33. Medical Advisory Secretariat. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont. Health Technol. Assess. Ser. 10(23), 1–57 (2010).
      Google Scholar
    • 34. Ward S, Scope A, Rafia R et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost–effectiveness analysis. Health Technol. Assess. 17(44), 1–302 (2013).
      Medline CASGoogle Scholar
    • 35. Kip M, Monteban H, Steuten L. Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective. J. Comp. Eff. Res. 4(5), 433–445 (2015).
      MedlineGoogle Scholar
    • 36. Bueno-de-Mesquita JM, Nuyten DS, Wesseling J et al. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann. Oncol. 21(1), 40–47 (2010).
      Medline CASGoogle Scholar